Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 15060135 
Pende M, et al. (2004) S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol Cell Biol 24, 3112-24 15060135
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download Sites

T412-p - p70S6K (mouse)
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  hepatocyte-liver, MEF (fibroblast)
 Cellular systems studied:  primary cells, primary cultured cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF, insulin increase
rapamycin EGF, insulin inhibit treatment-induced increase
PD184352 EGF, insulin no effect upon treatment-induced increase

T348-p - p90RSK (mouse)
Orthologous residues
p90RSK (human): T359‑p, p90RSK iso2 (human): T368‑p, p90RSK (mouse): T348‑p, p90RSK iso3 (mouse): , p90RSK (rat): T359‑p, p90RSK (chicken): T377‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  hepatocyte-liver, MEF (fibroblast)
 Cellular systems studied:  primary cells, primary cultured cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF, insulin increase
rapamycin EGF, insulin no effect upon treatment-induced increase
PD184352 EGF, insulin inhibit treatment-induced increase

S352-p - p90RSK (mouse)
Orthologous residues
p90RSK (human): S363‑p, p90RSK iso2 (human): S372‑p, p90RSK (mouse): S352‑p, p90RSK iso3 (mouse): , p90RSK (rat): S363‑p, p90RSK (chicken): S381‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  hepatocyte-liver, MEF (fibroblast)
 Cellular systems studied:  primary cells, primary cultured cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF, insulin increase
rapamycin EGF, insulin no effect upon treatment-induced increase
PD184352 EGF, insulin inhibit treatment-induced increase

S235-p - S6 (mouse)
Orthologous residues
S6 (human): S235‑p, S6 (mouse): S235‑p, S6 (rat): S235‑p, S6 (fruit fly): A234‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  hepatocyte-liver, MEF (fibroblast)
 Cellular systems studied:  primary cells, primary cultured cells
 Species studied:  mouse
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE p70S6K (mouse) genetic knockout/knockin of upstream enzyme, phospho-antibody, pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme
KINASE P70S6KB (mouse) genetic knockout/knockin of upstream enzyme, phospho-antibody, pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF, insulin increase
wortmannin EGF, insulin inhibit treatment-induced increase
rapamycin EGF, insulin inhibit treatment-induced increase
U0126 EGF, insulin inhibit treatment-induced increase more obvious in the S6K1-/- S6K2-/- cells
PD184352 EGF, insulin inhibit treatment-induced increase more obvious in the S6K1-/- S6K2-/- cells

S236-p - S6 (mouse)
Orthologous residues
S6 (human): S236‑p, S6 (mouse): S236‑p, S6 (rat): S236‑p, S6 (fruit fly): S235‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  hepatocyte-liver, MEF (fibroblast)
 Cellular systems studied:  primary cells, primary cultured cells
 Species studied:  mouse
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE P70S6KB (mouse) genetic knockout/knockin of upstream enzyme, phospho-antibody, pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme
KINASE p70S6K (mouse) genetic knockout/knockin of upstream enzyme, phospho-antibody, pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF, insulin increase
wortmannin EGF, insulin inhibit treatment-induced increase
rapamycin EGF, insulin inhibit treatment-induced increase
U0126 EGF, insulin inhibit treatment-induced increase more obvious in the S6K1-/- S6K2-/- cells
PD184352 EGF, insulin inhibit treatment-induced increase more obvious in the S6K1-/- S6K2-/- cells

S240-p - S6 (mouse)
Orthologous residues
S6 (human): S240‑p, S6 (mouse): S240‑p, S6 (rat): S240‑p, S6 (fruit fly): S239‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  hepatocyte-liver, MEF (fibroblast)
 Cellular systems studied:  primary cells, primary cultured cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF, insulin increase
wortmannin EGF, insulin inhibit treatment-induced increase
rapamycin EGF, insulin inhibit treatment-induced increase
U0126 EGF, insulin no effect upon treatment-induced increase
PD184352 EGF, insulin no effect upon treatment-induced increase

S244-p - S6 (mouse)
Orthologous residues
S6 (human): S244‑p, S6 (mouse): S244‑p, S6 (rat): S244‑p, S6 (fruit fly): V243‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  hepatocyte-liver, MEF (fibroblast)
 Cellular systems studied:  primary cells, primary cultured cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF, insulin increase
wortmannin EGF, insulin inhibit treatment-induced increase
rapamycin EGF, insulin inhibit treatment-induced increase
U0126 EGF, insulin no effect upon treatment-induced increase
PD184352 EGF, insulin no effect upon treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.